Successful medicine begins with target validation and target discovery. Finding the drugable targets remains pivotal to the future R&D success to pharmaceutical companies. HD Biosciences innovative Advanced Gene Manipulation (AGM™) technology and platform solutions serve the clients in the identification and validation of both known and novel targets to understand their contexts of diseases, accelerate the decisions toward Go

As one of well recognized strong holdings within the company's capabilities, HDB's target validation program has teamed with several major pharmaceutical companies for years to support their programs from oncology, metabolic diseases, translational medicine, to pharmacogenomics. The quality validation results for more than

•  Target knockdown, co-knockdown of isoforms, & target overexpression

•  Pathway dissecting & phenotypic study

•  Conventional knockout, knock-in; conditional regional, organ, or cell type specific knockout in mice

•  In vitro functional readout & evaluation

    or isogenic cell lines

•  MOA & signaling cascade

•  Region specific or cell type specific inducible/reversible transgenic mice

•  Targeting specific tissues for MOA study

•  BAC/YAC transgenic mice for humanized animal models

•  In vivo phenotypic characterizations in various disease models

•  Evaluation of target functional roles

•  shRNA or sgRNA library screening for target id

•  Characterization of target activities & correlations in cell lines with positive and negative effects

•  IHC, FACS, WB, qPCR for target engagement

•  Rescue study for target specificity confirmation

•  Multiple marker classes including DNA, RNA, protein &

•  Viral-based or nonviral-based vectors in specific cell, tissue, organ or systemic gene delivery

    microRNA markers

    & manipulation in vitro & in vivo

•  Genetically defined platform including both in vitro & in vivo

•  Transgenic technology for model generation; genotyping; breeding & characterization

    disease models

•  Targeted genome editing platform (CRISPR/cas 9) for knockout, knock-in of genome manipulation

•  Assay development using both mouse & human samples

    at cell types of interest

•  Bioinformatics supports